APA

Fleming D. R., Wolff S. N., Fay J. W., Brown R. A., Lynch J. P., Bolwell B. J., Stevens D. A., Goodman S. A., Greer J. P., Stein R. S., Pineiro L. A., Collins R. H., Goldsmith L. J., Herzig G. P. & Herzig R. H. (19991118). Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. : Leukemia & lymphoma.

Chicago

Fleming D R, Wolff S N, Fay J W, Brown R A, Lynch J P, Bolwell B J, Stevens D A, Goodman S A, Greer J P, Stein R S, Pineiro L A, Collins R H, Goldsmith L J, Herzig G P and Herzig R H. 19991118. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. : Leukemia & lymphoma.

Harvard

Fleming D. R., Wolff S. N., Fay J. W., Brown R. A., Lynch J. P., Bolwell B. J., Stevens D. A., Goodman S. A., Greer J. P., Stein R. S., Pineiro L. A., Collins R. H., Goldsmith L. J., Herzig G. P. and Herzig R. H. (19991118). Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. : Leukemia & lymphoma.

MLA

Fleming D R, Wolff S N, Fay J W, Brown R A, Lynch J P, Bolwell B J, Stevens D A, Goodman S A, Greer J P, Stein R S, Pineiro L A, Collins R H, Goldsmith L J, Herzig G P and Herzig R H. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. : Leukemia & lymphoma. 19991118.